The medicinal perspective of 2,4-thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

dc.contributor.authorKajal, Kumari
dc.contributor.authorSingh, Gurpreet
dc.contributor.authorPradhan, Tathagata
dc.contributor.authorBhurta, Deendyal
dc.contributor.authorMonga, Vikramdeep
dc.date.accessioned2024-01-21T10:38:22Z
dc.date.accessioned2024-08-13T12:05:18Z
dc.date.available2024-01-21T10:38:22Z
dc.date.available2024-08-13T12:05:18Z
dc.date.issued2022-06-18T00:00:00
dc.description.abstract2,4-Thiazolidinedione (2,4-TZD), commonly known as glitazone, is a ubiquitous heterocyclic pharmacophore possessing a plethora of pharmacological activities and offering a vast opportunity for structural modification. The diverse range of biological activities endowed with a novel mode of action, low cost, and easy synthesis has attracted the attention of medicinal chemists. Several researchers have integrated the TZD core with different structural fragments to develop a wide range of lead molecules against various clinical disorders. The most common sites for structural modifications at the 2,4-TZD nucleus are the N-3 and the active methylene at C-5. The review covers the recent development of TZD derivatives such as antimicrobial, anticancer, and antidiabetic agents. Various 2,4-TZD based agents or drugs, which are either under clinical development or in the market, are discussed in the study. Different synthetic methodologies for synthesizing the 2,4-TZD core are also included in the manuscript. The importance of various substitutions at N-3 and C-5 and the mechanisms of action and structure�activity relationships are also discussed. We hope this study will serve as a valuable tool for the scientific community engaged in the structural exploitation of the 2,4-TZD core for developing novel drug m\olecules for life-threatening ailments. � 2022 Deutsche Pharmazeutische Gesellschaft.en_US
dc.identifier.doi10.1002/ardp.202100517
dc.identifier.issn3656233
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/3547
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1002/ardp.202100517
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.subjectanticanceren_US
dc.subjectantidiabeticen_US
dc.subjectantimicrobialen_US
dc.subjectbiological activityen_US
dc.subjectheterocyclic compoundsen_US
dc.subjectin silico studiesen_US
dc.subjectmolecular dockingen_US
dc.subjectSARen_US
dc.subjectthiazolidinedioneen_US
dc.titleThe medicinal perspective of 2,4-thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A reviewen_US
dc.title.journalArchiv der Pharmazieen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files